Loading…
Loading…
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cencora, Inc. (COR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.
Cencora (COR) reported earnings 30 days ago. What's next for the stock?
COR launches CGT Enablement to help health systems build and scale cell and gene therapy programs with financial, operational and access support.
Cencora raised its fiscal 2026 EPS outlook as specialty businesses fueled stronger profit growth despite mix, pricing and financing pressures.
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora today launched a service to help health systems evaluate, build and scale cell and gene therapy (CGT) programs. Offered through Accelerate Pharmacy Solutions, Cell and Gene Therapy Enablement is designed to help health systems strengthen operational readiness and program execution to reduce barriers to care and expand patient access to advanced therapies. “Cell and gene therapies have the potential to transform care for patients with serious and compl.